121 related articles for article (PubMed ID: 10493000)
21. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
[TBL] [Abstract][Full Text] [Related]
23. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
Gels ME; Hoekstra HJ; Sleijfer DT; Marrink J; de Bruijn HW; Molenaar WM; Freling NJ; Droste JH; Schraffordt Koops H
J Clin Oncol; 1995 May; 13(5):1188-94. PubMed ID: 7537802
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in low-stage nonseminomatous testicular cancer.
Moul JW; Heidenreich A
Oncology (Williston Park); 1996 Sep; 10(9):1359-68, 1374; discussion 1377-8. PubMed ID: 8882926
[TBL] [Abstract][Full Text] [Related]
25. Management of germ cell testicular cancer with pulmonary metastases.
Schnorrer M; Ondrus D; Cársky S; Hornák M; Belan V; Kausitz J; Matośka J
Neoplasma; 1996; 43(1):47-50. PubMed ID: 8843960
[TBL] [Abstract][Full Text] [Related]
26. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
[TBL] [Abstract][Full Text] [Related]
27. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
28. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
Albers P; Siener R; Kliesch S; Weissbach L; Krege S; Sparwasser C; Schulze H; Heidenreich A; de Riese W; Loy V; Bierhoff E; Wittekind C; Fimmers R; Hartmann M;
J Clin Oncol; 2003 Apr; 21(8):1505-12. PubMed ID: 12697874
[TBL] [Abstract][Full Text] [Related]
30. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
31. Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.
Inci K; Dogan HS; Akdogan B; Baydar DE; Ergen A; Ozen H
Urol Oncol; 2011; 29(1):38-42. PubMed ID: 19269199
[TBL] [Abstract][Full Text] [Related]
32. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
33. Clinical stage I testis cancer: long-term outcome of patients on surveillance.
Sogani PC; Perrotti M; Herr HW; Fair WR; Thaler HT; Bosl G
J Urol; 1998 Mar; 159(3):855-8. PubMed ID: 9474168
[TBL] [Abstract][Full Text] [Related]
34. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors.
Sturgeon JF; Jewett MA; Alison RE; Gospodarowicz MK; Blend R; Herman S; Richmond H; Thomas G; Duncan W; Munro A
J Clin Oncol; 1992 Apr; 10(4):564-8. PubMed ID: 1312585
[TBL] [Abstract][Full Text] [Related]
35. Germ cell testicular tumors in clinical stage A and normal values of serum tumor mark-ers post-orchiectomy: the experience in the management of 300 consecutive patients.
Argirović Dj
J BUON; 2005; 10(2):195-200. PubMed ID: 17343328
[TBL] [Abstract][Full Text] [Related]
36. [Treatment outcome on 52 patients with 53 testicular germ cell tumors].
Yokoyama M; Nemoto K; Kanemura M; Kitahara K; Oda H; Murata H; Matsunaga Y
Hinyokika Kiyo; 1998 Nov; 44(11):789-94. PubMed ID: 9893223
[TBL] [Abstract][Full Text] [Related]
37. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
38. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy of testicular cancer: 10-year experience.
Ondrus D; Hornák M; Matoska J; Kausitz J; Belan V; Cársky S
Neoplasma; 1993; 40(4):247-53. PubMed ID: 7505886
[TBL] [Abstract][Full Text] [Related]
40. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
